Form 10-Q Centessa Pharmaceuticals For: Mar 31 streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
– Company advances innovative rare disease and immuno-oncology portfolio toward ‘4x24’ goal of four registrational programs in 2024 – – Poster presentation at ASCO 2022. | May 16, 2022
LIPAC Oncology Announces Appointment of Josh Hamermesh to the Board of Directors
Industry Veteran Brings More Than 20 Years of Biotech Leadership Experience
News provided by
Share this article
Share this article
MENLO PARK, Calif., May 6, 2021 /PRNewswire/ LIPAC Oncology LLC., a pharmaceutical company utilizing its liposome-bound nano-technology platform to provide precision targeted cancer drugs for the treatment of multiple tumor types, today announced the appointment of Josh Hamermesh as an independent board director. Josh is a noted expert in driving and supporting the growth of innovative companies thanks to his two decades of leadership experience in the biotechnology industry, said Will Robberts, President of LIPAC Oncology. We welcome Josh to the Board and look forward to his insights and contributions around both corporate and business development, strategy and commercialization as we continue to advance our oncology pipeline and build our business.